ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$70.96

Market cap

$1.61B

P/E Ratio

13.7

Dividend/share

N/A

EPS

$5.18

Enterprise value

$1.8B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 93

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused ...

Highlights
Ani Pharmaceuticals's net income has surged by 188% YoY and by 8% QoQ
The company's equity rose by 26% YoY and by 7% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com
Peers: JAZZ TEVA CLDX PFE

Key stats

What are the main financial stats of ANIP

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
-0.18%
1 week
1.92%
1 month
-3.57%
1 year
-18.69%
YTD
-10.11%
QTD
-2.33%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$635.8M
Operating income
$160.27M
Net income
$116.84M
Gross margin
61.1%
Net margin
11.2%
ANIP's operating margin has surged by 196% year-on-year and by 16% since the previous quarter
Ani Pharmaceuticals's net income has surged by 188% YoY and by 8% QoQ
The net margin has soared by 129% YoY
Ani Pharmaceuticals's revenue has increased by 26% YoY and by 6% from the previous quarter

Price vs fundamentals

How does ANIP's price correlate with its fundamentals

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
ANIP P/E details
P/E
13.7
P/B
2.56
P/S
1.48
EV/EBIT
10.42
EV/EBITDA
6.99
EV/Sales
1.73
ANIP's P/E is 24% below its last 4 quarters average of 18.1
The company's EPS rose by 7% QoQ
The company's equity rose by 26% YoY and by 7% QoQ
The P/B is 15% below the last 4 quarters average of 3.0 and 5% below the 5-year quarterly average of 2.7
The price to sales (P/S) is 30% lower than the 5-year quarterly average of 2.1 and 18% lower than the last 4 quarters average of 1.8
Ani Pharmaceuticals's revenue has increased by 26% YoY and by 6% from the previous quarter

Efficiency

How efficient is Ani Pharmaceuticals business performance
The ROA has soared by 172% YoY and by 5% from the previous quarter
Ani Pharmaceuticals's ROIC has soared by 141% YoY and by 9% from the previous quarter
The return on equity has surged by 127% year-on-year and by 2% since the previous quarter
The company's return on sales has surged by 91% YoY

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 68% more than its total liabilities
ANIP's quick ratio is up by 16% year-on-year
Ani Pharmaceuticals's total assets has increased by 11% YoY and by 4.9% from the previous quarter
The debt is 4.7% lower than the equity
The company's equity rose by 26% YoY and by 7% QoQ
The debt to equity has decreased by 23% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.